The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study

There is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large longitudinal studies of endogenous reactivation (relapse) and reinfection tuberculosis are lacking. We hypothesize a relationship between relap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases Jg. 58; H. 12; S. 1676
Hauptverfasser:	Marx, Florian M, Dunbar, Rory, Enarson, Donald A, Williams, Brian G, Warren, Robin M, van der Spuy, Gian D, van Helden, Paul D, Beyers, Nulda
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.06.2014
Schlagworte:	Adult Child Child, Preschool DNA Fingerprinting Female Humans Infant Infant, Newborn Longitudinal Studies Male Mycobacterium tuberculosis - genetics Recurrence Retrospective Studies Time Factors Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology Young Adult recurrence South Africa reinfection Mycobacterium tuberculosis DNA fingerprinting
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	There is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large longitudinal studies of endogenous reactivation (relapse) and reinfection tuberculosis are lacking. We hypothesize a relationship between relapse vs reinfection and the time between treatment completion and recurrent disease. Population-based retrospective cohort study on all smear-positive tuberculosis cases successfully treated between 1996 and 2008 in a suburban setting in Cape Town, South Africa. Inverse gaussian distributions were fitted to observed annual rates of relapse and reinfection, distinguished by DNA fingerprinting of Mycobacterium tuberculosis strains recultured from diagnostic samples. Paired DNA fingerprint data were available for 130 (64%) of 203 recurrent smear-positive tuberculosis cases in the 13-year study period. Reinfection accounted for 66 (51%) of 130 recurrent cases overall, 9 (20%) of 44 recurrent cases within the first year, and 57 (66%) of 86 thereafter (P < .001). The relapse rate peaked at 3.93% (95% confidence interval [CI], 2.35%-5.96%) per annum 0.35 (95% CI, .15-.45) years after treatment completion. The reinfection tuberculosis rate peaked at 1.58% (95% CI, .94%-2.46%) per annum 1.20 (95% CI, .55-1.70) years after completion. To our knowledge, this is the first study of sufficient size and duration using DNA fingerprinting to investigate tuberculosis relapse and reinfection over a lengthy period. Relapse occurred early after treatment completion, whereas reinfection dominated after 1 year and accounted for at least half of recurrent disease. This temporal relationship may explain the high variability in reinfection observed across smaller studies. We speculate that follow-up time in antituberculosis drug trials should take reinfection into account.
AbstractList	There is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large longitudinal studies of endogenous reactivation (relapse) and reinfection tuberculosis are lacking. We hypothesize a relationship between relapse vs reinfection and the time between treatment completion and recurrent disease. Population-based retrospective cohort study on all smear-positive tuberculosis cases successfully treated between 1996 and 2008 in a suburban setting in Cape Town, South Africa. Inverse gaussian distributions were fitted to observed annual rates of relapse and reinfection, distinguished by DNA fingerprinting of Mycobacterium tuberculosis strains recultured from diagnostic samples. Paired DNA fingerprint data were available for 130 (64%) of 203 recurrent smear-positive tuberculosis cases in the 13-year study period. Reinfection accounted for 66 (51%) of 130 recurrent cases overall, 9 (20%) of 44 recurrent cases within the first year, and 57 (66%) of 86 thereafter (P < .001). The relapse rate peaked at 3.93% (95% confidence interval [CI], 2.35%-5.96%) per annum 0.35 (95% CI, .15-.45) years after treatment completion. The reinfection tuberculosis rate peaked at 1.58% (95% CI, .94%-2.46%) per annum 1.20 (95% CI, .55-1.70) years after completion. To our knowledge, this is the first study of sufficient size and duration using DNA fingerprinting to investigate tuberculosis relapse and reinfection over a lengthy period. Relapse occurred early after treatment completion, whereas reinfection dominated after 1 year and accounted for at least half of recurrent disease. This temporal relationship may explain the high variability in reinfection observed across smaller studies. We speculate that follow-up time in antituberculosis drug trials should take reinfection into account. There is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large longitudinal studies of endogenous reactivation (relapse) and reinfection tuberculosis are lacking. We hypothesize a relationship between relapse vs reinfection and the time between treatment completion and recurrent disease.BACKGROUNDThere is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large longitudinal studies of endogenous reactivation (relapse) and reinfection tuberculosis are lacking. We hypothesize a relationship between relapse vs reinfection and the time between treatment completion and recurrent disease.Population-based retrospective cohort study on all smear-positive tuberculosis cases successfully treated between 1996 and 2008 in a suburban setting in Cape Town, South Africa. Inverse gaussian distributions were fitted to observed annual rates of relapse and reinfection, distinguished by DNA fingerprinting of Mycobacterium tuberculosis strains recultured from diagnostic samples.METHODSPopulation-based retrospective cohort study on all smear-positive tuberculosis cases successfully treated between 1996 and 2008 in a suburban setting in Cape Town, South Africa. Inverse gaussian distributions were fitted to observed annual rates of relapse and reinfection, distinguished by DNA fingerprinting of Mycobacterium tuberculosis strains recultured from diagnostic samples.Paired DNA fingerprint data were available for 130 (64%) of 203 recurrent smear-positive tuberculosis cases in the 13-year study period. Reinfection accounted for 66 (51%) of 130 recurrent cases overall, 9 (20%) of 44 recurrent cases within the first year, and 57 (66%) of 86 thereafter (P < .001). The relapse rate peaked at 3.93% (95% confidence interval [CI], 2.35%-5.96%) per annum 0.35 (95% CI, .15-.45) years after treatment completion. The reinfection tuberculosis rate peaked at 1.58% (95% CI, .94%-2.46%) per annum 1.20 (95% CI, .55-1.70) years after completion.RESULTSPaired DNA fingerprint data were available for 130 (64%) of 203 recurrent smear-positive tuberculosis cases in the 13-year study period. Reinfection accounted for 66 (51%) of 130 recurrent cases overall, 9 (20%) of 44 recurrent cases within the first year, and 57 (66%) of 86 thereafter (P < .001). The relapse rate peaked at 3.93% (95% confidence interval [CI], 2.35%-5.96%) per annum 0.35 (95% CI, .15-.45) years after treatment completion. The reinfection tuberculosis rate peaked at 1.58% (95% CI, .94%-2.46%) per annum 1.20 (95% CI, .55-1.70) years after completion.To our knowledge, this is the first study of sufficient size and duration using DNA fingerprinting to investigate tuberculosis relapse and reinfection over a lengthy period. Relapse occurred early after treatment completion, whereas reinfection dominated after 1 year and accounted for at least half of recurrent disease. This temporal relationship may explain the high variability in reinfection observed across smaller studies. We speculate that follow-up time in antituberculosis drug trials should take reinfection into account.CONCLUSIONSTo our knowledge, this is the first study of sufficient size and duration using DNA fingerprinting to investigate tuberculosis relapse and reinfection over a lengthy period. Relapse occurred early after treatment completion, whereas reinfection dominated after 1 year and accounted for at least half of recurrent disease. This temporal relationship may explain the high variability in reinfection observed across smaller studies. We speculate that follow-up time in antituberculosis drug trials should take reinfection into account.
Author	Dunbar, Rory Warren, Robin M Beyers, Nulda Williams, Brian G Marx, Florian M van Helden, Paul D Enarson, Donald A van der Spuy, Gian D
Author_xml	– sequence: 1 givenname: Florian M surname: Marx fullname: Marx, Florian M organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University Department for Pediatric Pneumology and Immunology, Charité-Universitätsmedizin, Berlin, Germany – sequence: 2 givenname: Rory surname: Dunbar fullname: Dunbar, Rory organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University – sequence: 3 givenname: Donald A surname: Enarson fullname: Enarson, Donald A organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University International Union Against Tuberculosis and Lung Disease, Paris, France – sequence: 4 givenname: Brian G surname: Williams fullname: Williams, Brian G organization: DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa – sequence: 5 givenname: Robin M surname: Warren fullname: Warren, Robin M organization: DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, US/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg Campus, Cape Town – sequence: 6 givenname: Gian D surname: van der Spuy fullname: van der Spuy, Gian D organization: DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, US/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg Campus, Cape Town – sequence: 7 givenname: Paul D surname: van Helden fullname: van Helden, Paul D organization: DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, US/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg Campus, Cape Town – sequence: 8 givenname: Nulda surname: Beyers fullname: Beyers, Nulda organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24647020$$D View this record in MEDLINE/PubMed
BookMark	eNpNkD1PwzAYhC1URGlh4QcgjyyB1_lwbDZU8SVVYukeOfYbNSixgz8q9d8TRJEYTnfDczfciiyss0jIDYN7BrJ40L2ZlZjgZ-SSVUWd8Uqyxb-8JKsQPgEYE1BdkGVe8rKGHC7JYbdHGnGcnFcDNUerxl4H6jrqcVBTQKqsmXNvO9Sxd5bG1KLXaXChD1R1ET0NSWsMoUsDjR5VHNHGR6rmWvQuTD_FA1Lt9s5HGmIyxyty3qkh4PXJ12T38rzbvGXbj9f3zdM202XBY4aihbIDNAxakIKrUla5lELVlW6NYAok5hqQa1UXHcsV8NYAFkZUHLDM1-Tud3by7ithiM3YB43DoCy6FJr5IJBVLXI-o7cnNLUjmmby_aj8sfm7Kv8Gkx5vmg
CitedBy_id	crossref_primary_10_1016_S2214_109X_24_00467_4 crossref_primary_10_1093_cid_ciad589 crossref_primary_10_1093_ofid_ofx172 crossref_primary_10_1007_s15010_025_02500_4 crossref_primary_10_1111_tid_13659 crossref_primary_10_1183_13993003_01089_2018 crossref_primary_10_1055_a_1934_8303 crossref_primary_10_1093_cid_ciaa470 crossref_primary_10_1093_femspd_ftx020 crossref_primary_10_1016_j_tube_2017_01_007 crossref_primary_10_1007_s00103_017_2660_4 crossref_primary_10_1136_thoraxjnl_2020_215449 crossref_primary_10_1016_j_epidem_2015_10_001 crossref_primary_10_1038_s41598_019_54561_9 crossref_primary_10_1002_cti2_1176 crossref_primary_10_1080_23744235_2024_2313668 crossref_primary_10_1016_j_ijid_2021_12_344 crossref_primary_10_1093_cid_civ195 crossref_primary_10_1371_journal_pone_0144487 crossref_primary_10_1136_jech_2022_219622 crossref_primary_10_1371_journal_pmed_1002638 crossref_primary_10_1371_journal_pone_0143552 crossref_primary_10_7326_M21_3170 crossref_primary_10_1186_s12913_020_4927_y crossref_primary_10_1371_journal_pone_0172748 crossref_primary_10_3389_fcimb_2021_638990 crossref_primary_10_1016_S1473_3099_24_00814_4 crossref_primary_10_1016_S2352_4642_17_30150_5 crossref_primary_10_1016_j_cmi_2021_09_022 crossref_primary_10_1093_cid_ciac965 crossref_primary_10_1128_JCM_01696_17 crossref_primary_10_1016_S2213_2600_19_30370_4 crossref_primary_10_1016_j_tube_2017_11_009 crossref_primary_10_1097_EDE_0000000000001305 crossref_primary_10_1053_j_semnuclmed_2016_12_003 crossref_primary_10_3389_fgene_2020_600692 crossref_primary_10_5588_ijtldopen_24_0552 crossref_primary_10_1038_s41541_023_00761_4 crossref_primary_10_1371_journal_pone_0218606 crossref_primary_10_3389_fcimb_2020_00150 crossref_primary_10_1016_S1473_3099_15_00071_7 crossref_primary_10_1080_23744235_2016_1262059 crossref_primary_10_1016_j_jiph_2025_102912 crossref_primary_10_1093_infdis_jiv447 crossref_primary_10_1080_23744235_2020_1794027 crossref_primary_10_1159_000509522 crossref_primary_10_1186_s12879_019_4561_7 crossref_primary_10_5588_ijtldopen_23_0451 crossref_primary_10_1513_AnnalsATS_201905_418OC crossref_primary_10_3390_biomedicines12050954 crossref_primary_10_1038_s41572_024_00504_2 crossref_primary_10_5588_ijtldopen_24_0222 crossref_primary_10_1016_j_meegid_2017_08_021 crossref_primary_10_1093_infdis_jiu574 crossref_primary_10_1183_13993003_01646_2015 crossref_primary_10_1016_j_tube_2016_05_008 crossref_primary_10_1016_S1473_3099_18_30477_8 crossref_primary_10_1016_j_meegid_2019_103948 crossref_primary_10_1080_17441692_2021_1940235 crossref_primary_10_1016_j_tube_2015_04_003 crossref_primary_10_1093_infdis_jiae275 crossref_primary_10_1016_j_ijmm_2016_05_007 crossref_primary_10_1016_S2213_2600_15_00458_0 crossref_primary_10_1136_bmjopen_2021_051521 crossref_primary_10_1371_journal_pone_0196815 crossref_primary_10_1371_journal_pmed_1004237 crossref_primary_10_1371_journal_pone_0294254 crossref_primary_10_1128_iai_00535_23 crossref_primary_10_1186_s12916_021_01932_7 crossref_primary_10_1016_j_chaos_2024_114649 crossref_primary_10_1371_journal_pmed_1002891 crossref_primary_10_1001_jamanetworkopen_2024_27266 crossref_primary_10_3389_fmicb_2023_1115295 crossref_primary_10_1038_nm_4177 crossref_primary_10_1093_cid_ciad557 crossref_primary_10_1186_s12976_017_0049_6 crossref_primary_10_1016_j_arbres_2022_05_010 crossref_primary_10_1186_s12916_016_0589_3 crossref_primary_10_1186_s12916_023_02992_7 crossref_primary_10_1186_s12977_021_00559_z crossref_primary_10_1016_j_ijid_2018_06_013 crossref_primary_10_1186_s13550_020_0591_9 crossref_primary_10_1097_IAE_0000000000003134 crossref_primary_10_1128_microbiolspec_TBTB2_0009_2016 crossref_primary_10_1002_jia2_25721 crossref_primary_10_3389_fmicb_2019_03154 crossref_primary_10_1016_j_tube_2022_102174 crossref_primary_10_1183_13993003_00716_2016 crossref_primary_10_1186_s12879_020_05515_4 crossref_primary_10_12688_gatesopenres_13179_1 crossref_primary_10_1016_j_clinthera_2018_01_013 crossref_primary_10_1093_jac_dkae256 crossref_primary_10_1016_j_ijid_2021_07_057 crossref_primary_10_1097_QAI_0000000000002497 crossref_primary_10_1111_imr_12270 crossref_primary_10_1371_journal_pone_0248846
ContentType	Journal Article
Copyright	The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml	– notice: The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/cid/ciu186
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1537-6591
ExternalDocumentID	24647020
Genre	Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- ..I .2P .GJ .I3 .ZR 08P 0R~ 1KJ 1TH 29B 2AX 2WC 36B 3O- 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAYOK ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABSMQ ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACHIC ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFQV AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS AQVQM ASPBG ATGXG AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C1A C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B M49 MBLQV MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NPM NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H Y6R YAYTL YKOAZ YXANX ZGI ~91 ~S- 7X8 AJBYB
ID	FETCH-LOGICAL-c436t-e8b04f0ed10b0986a4952998a75cbd81a09e2c0e6ca73f12a06bd0e3d8560e42
IEDL.DBID	7X8
ISICitedReferencesCount	112
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000337031700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1537-6591
IngestDate	Thu Oct 02 10:55:21 EDT 2025 Thu Apr 03 06:57:59 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	12
Keywords	recurrence South Africa reinfection Mycobacterium tuberculosis DNA fingerprinting
Language	English
License	The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c436t-e8b04f0ed10b0986a4952998a75cbd81a09e2c0e6ca73f12a06bd0e3d8560e42
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/cid/article-pdf/58/12/1676/9412191/ciu186.pdf
PMID	24647020
PQID	1530957826
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1530957826 pubmed_primary_24647020
PublicationCentury	2000
PublicationDate	2014-06-15
PublicationDateYYYYMMDD	2014-06-15
PublicationDate_xml	– month: 06 year: 2014 text: 2014-06-15 day: 15
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical infectious diseases
PublicationTitleAlternate	Clin Infect Dis
PublicationYear	2014
SSID	ssj0011805
Score	2.4718676
Snippet	There is increasing evidence from tuberculosis high-burden settings that exogenous reinfection contributes considerably to recurrent disease. However, large...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1676
SubjectTerms	Adult Child Child, Preschool DNA Fingerprinting Female Humans Infant Infant, Newborn Longitudinal Studies Male Mycobacterium tuberculosis - genetics Recurrence Retrospective Studies Time Factors Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology Young Adult
Title	The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study
URI	https://www.ncbi.nlm.nih.gov/pubmed/24647020 https://www.proquest.com/docview/1530957826
Volume	58
WOSCitedRecordID	wos000337031700006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhxX8aNCF6DTZumqRcRcfDgDHMYZG4lzQIDQzt2md_vSxfnJAheSi8PSvKS9zXvy_ch9KAs1ZRrn_gmVsQJdpHUhoJYroRPmY5s40Xw-RFNJmI-j6fdgVvZ0Sr7PbHZqHWu3Bn5I6xMQANQz_jz6os41yjXXe0sNLbRIAAo47I6mm-6CFQ0FEYIjQgPY9rLk8bBo4KpVouaCv47tGxKzOjwvx93hA46cIlf2mw4RlsmO0F74659forWkBS4E6NaYt2a0Zc4t9hdaVmVBstMw3vP0MpwVaemUPUyLxclbvzEcVk3Hou2XuIflvoTlhBWFXl_cRM7492iwo167Rmajd5mr--kM14gigW8IkakHrOe0dRLvVhwCX9RULaEjEKVakGlFxtfeYYrGQWW-tLjqfZMoAXgJ8P8c7ST5Zm5RBjwnY610IIzywRXaWiokko56S9jYzZE9_2AJpDXrlkhM5PXZbIZ0iG6aGclWbUCHInPOIsA5179Ifoa7QPGYY7dRcMbNLCwqs0t2lXralEWd03CwHMyHX8DnT_PEA
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+temporal+dynamics+of+relapse+and+reinfection+tuberculosis+after+successful+treatment%3A+a+retrospective+cohort+study&rft.jtitle=Clinical+infectious+diseases&rft.au=Marx%2C+Florian+M&rft.au=Dunbar%2C+Rory&rft.au=Enarson%2C+Donald+A&rft.au=Williams%2C+Brian+G&rft.date=2014-06-15&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=58&rft.issue=12&rft.spage=1676&rft_id=info:doi/10.1093%2Fcid%2Fciu186&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon